105 related articles for article (PubMed ID: 673774)
1. [Survey of anthracyclines derivatives in haematology (author's transl)].
Jacquillat C; Weil M; Auclerc MF; Maral J; Schaison G; Boiron M; Bernard J
Nouv Presse Med; 1978 Jun; 7(23):2061-6. PubMed ID: 673774
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
Jaenke RS; Deprez-DeCampeneere D; Trouet A
Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity of detorubicin: a new anthracycline derivative.
Jacquillat C; Auclerc MF; Weil M; Maral J; Degos L; Auclerc G; Tobelem G; Schaison G; Bernard J
Cancer Treat Rep; 1979 May; 63(5):889-93. PubMed ID: 455330
[TBL] [Abstract][Full Text] [Related]
4. In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia.
Marie JP; Thevenin D; Zittoun R
Nouv Rev Fr Hematol (1978); 1985; 27(3):163-7. PubMed ID: 3862071
[TBL] [Abstract][Full Text] [Related]
5. [Cardiotoxicity of daunorubicin and aclacinomycin A in patients with acute leukemia].
Haruyama H; Shimazaki C; Nakanishi S; Hamami T; Nisio A; Isemura T; Katsume H; Nakagawa M; Ijichi H
Gan To Kagaku Ryoho; 1982 Mar; 9(3):516-21. PubMed ID: 6964037
[TBL] [Abstract][Full Text] [Related]
6. Experimental evaluation of anthracycline analogs.
Casazza AM
Cancer Treat Rep; 1979 May; 63(5):835-44. PubMed ID: 455325
[TBL] [Abstract][Full Text] [Related]
7. [Models of preclinical studies of anthracyclines].
Fizames C
Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of acute leukemia in the adult. Role of anthracyclines].
Gisselbrecht C; Lepage E; Lenoble M; Marty M; Boiron M
Pathol Biol (Paris); 1987 Jan; 35(1):69-74. PubMed ID: 3550615
[TBL] [Abstract][Full Text] [Related]
9. Clinical studies with daunorubicin-DNA and adriamycin-DNA complexes: a review.
Trouet A; Sokal G
Cancer Treat Rep; 1979 May; 63(5):895-8. PubMed ID: 287556
[TBL] [Abstract][Full Text] [Related]
10. [Clinical pharmacology of idarubicin].
Robak T
Acta Haematol Pol; 1993; 24(4):315-26. PubMed ID: 8303977
[TBL] [Abstract][Full Text] [Related]
11. [Rubidazone (22 050 RP): clinical study. Phase II trial in solid tumors and lymphomas (author's transl)].
Chauvergne J; Cappelaere P; Carton M; Gary-Bobo J; Klein T
Bull Cancer; 1978; 65(1):19-24. PubMed ID: 667371
[TBL] [Abstract][Full Text] [Related]
12. Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group Study.
Bickers J; Benjamin R; Wilson H; Eyre H; Hewlett J; McCredie K
Cancer Treat Rep; 1981; 65(5-6):427-30. PubMed ID: 6940659
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
[TBL] [Abstract][Full Text] [Related]
15. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
[TBL] [Abstract][Full Text] [Related]
16. Changes in the toxicity and therapeutic efficacy of daunorubicin linked with a biodegradable carrier.
Hrdina R; Bogusová TA; Kunová A; Kvĕtina J
Neoplasma; 1991; 38(3):265-73. PubMed ID: 1857447
[TBL] [Abstract][Full Text] [Related]
17. Syntheses and biological activities of 3'-azido disaccharide analogues of daunorubicin against drug-resistant leukemia.
Zhang G; Fang L; Zhu L; Zhong Y; Wang PG; Sun D
J Med Chem; 2006 Mar; 49(5):1792-9. PubMed ID: 16509594
[TBL] [Abstract][Full Text] [Related]
18. [The role of daunorubicin in induction therapy for adult acute myeloid leukemia].
Usui N; Dobashi N; Asai O; Yano S; Kato A; Osawa H; Uno S; Katori M; Nagamine M; Yahagi Y; Yamaguchi Y; Saito T; Kasama K; Takei Y; Ogihara A; Yamazaki H; Kobayashi T; Tajima N; Ogawa M; Kuraishi Y
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1152-9. PubMed ID: 10945010
[TBL] [Abstract][Full Text] [Related]
19. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
Young CW; Raymond V
Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
[No Abstract] [Full Text] [Related]
20. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
Johnson RK; Chitnis MP; Embrey WM; Gregory EB
Cancer Treat Rep; 1978 Oct; 62(10):1535-47. PubMed ID: 709555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
